Clinical Trial

A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy, safety and tolerability of HS-20093 compared with active surveillance as consolidation therapy after chemoradiotherapy in participants with limited-stage small cell lung cancer.
Trial Details
NCT Number NCT06526624
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Limited-stage Small-cell Lung Cancer
Enrollment 406 participants
Start Date 2024-09-30
Primary Completion 2027-11-30 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-30